Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Everest Organics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Everest Organics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Organics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Everest Organics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Everest Organics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Organics (BOM:524790) has a Buyback Yield % of 0.00 as of Aug. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Everest Organics and its competitors. According to the industry distribution chart, Everest Organics ranks #999999 out of 267 companies in the Drug Manufacturers industry.
Is Everest Organics' Buyback Yield % too high?
Everest Organics' current Buyback Yield % is 0.00. Based on the distribution chart, Everest Organics ranks #999999 out of 267 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Everest Organics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Everest Organics' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Everest Organics ranks #999999 out of 267 companies for Buyback Yield %. This places Everest Organics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Everest Organics and its competitors. Everest Organics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Organics stock overvalued right now?
Based on GuruFocus' analysis, Everest Organics (BOM:524790) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹129.17, compared to a current price of ₹286.95 — trading 122.1% above its estimated fair value. The current Buyback Yield % is 0.00. Everest Organics' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Everest Organics (BOM:524790), the current Buyback Yield % is 0.00 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Organics (BOM:524790) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Organics stock appears to be overvalued.
The current stock price of ₹286.95 is trading 122.1% above its estimated GF Value™ of ₹129.17.
GuruFocus considers Everest Organics to be Significantly Overvalued.
Key valuation signals for BOM:524790:
Buyback Yield %: 0.00
GF Value™: ₹129.17 vs. price of ₹286.95 (122.1% above fair value)
No single metric tells the full story. See the BOM:524790 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Organics Ltd is a pharmaceutical company. It is focused on manufacturing active pharmaceutical ingredients and intermediaries. The products offered by the company include Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole, and others. The company operates in one primary business segment namely Active Pharmaceutical Ingredients (API) and their intermediaries. Geographically, it derives a majority of its revenue from India.
53GF Score
Get the complete analysis for BOM:524790
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524790 has been successfully added to your 
